CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Make some room on ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond to traditional medications.

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

Duloxetine is an antidepressant, with a specific batch having been recalled due to the presence of potentially cancer-causing impurities.

Those on the extreme end of the depression spectrum face symptoms that impact their daily activities too and not just their ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...